| Strain Name |
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Ctla4tm1(CTLA4)Bcgen/Bcgen
|
Common Name | B-hPD-1/hCTLA4 mice |
| Background | C57BL/6 | Catalog number | 120519 |
|
Related Genes |
PD-1 (Programmed death-1) ； CTLA4 (Cytotoxic T-lymphocyte-associated protein 4,CD152) |
||
|
NCBI Gene ID |
18566,12477 | ||
mRNA expression analysis
Strain specific analysis of PD-1 and CTLA4 gene expression in WT and hPD-1/hCTLA4 mice by RT-PCR. Mouse Pd-1 and Ctla4 mRNA were detectable only in splenocytes of wild-type (+/+) mice. Human PD-1 and CTLA4 mRNA were detectable only in H/H, but not in +/+ mice.
Protein expression analysis
Combination therapy of anti-human PD-1 antibody and anti-human CTLA4 antibody
Antitumor activity of anti-human PD-1 antibody combined with anti-human CTLA4 antibody in B-hPD-1/hCTLA4 mice. (A) Anti-human PD-1 antibody combined with anti-human CTLA4 antibody inhibited MC38 tumor growth in B-hPD-1/hCTLA4 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hCTLA4 mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with pembrolizumab and ipilimumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab and ipilimumab shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCTLA4 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hCTLA4 antibodies. Values are expressed as mean ± SEM.
